Aspira Women’s Health (NASDAQ:AWH) Research Coverage Started at StockNews.com

Posted by Tyrone Williams on Nov 27th, 2024

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a research report sent to investors on Monday. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Get Our Latest Stock Analysis on AWH

Aspira Women’s Health Price Performance

Shares of AWH stock opened at $0.81 on Monday. The business’s fifty day moving average price is $0.83 and its 200 day moving average price is $1.28. The firm has a market capitalization of $13.50 million, a PE ratio of -0.67 and a beta of 1.44. Aspira Women’s Health has a 1-year low of $0.67 and a 1-year high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health as of its most recent filing with the Securities & Exchange Commission. 12.19% of the stock is currently owned by institutional investors and hedge funds.

About Aspira Women’s Health

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.